Treatment strategies for myeloproliferative neoplasms in Ruxolitinib era

Author: Jie BAI ¹ ; Li-xia FU ¹ ; Zong-hong SHAO ¹
Author Information

1. Department of Hematology, Second Hospital Affiliated to Tianjin Medical University Tianjin 300052, China
Publication Type:Journal Article
Keywords: ruxolitinib; myeloproliferative neoplasm; treatment therapy
From: Chinese Journal of Practical Internal Medicine 2019;39(02):123-126
CountryChina
Language:Chinese
Abstract: The different types of Ph-negative myeloproliferative neoplasm(MPN) possess the same JAK2V617 F mutation. JAK2 inhibitor, ruxolitinib, is only valid in some of MPN, which indicates JAK2 target is not the only molecular pathway of MPN. Epigenetic genes mutations, including TET2 and ASXL1, are involved in the progression and transformation of MPN. In addition, avoiding thromboembolism and reducing the risk of transformation into acute leukemia(AL) or myelofibrosis(MF) still is the therapeutic goal of polycythemia vera(PV) and essential thrombocytosis(ET). The goal of treatment in primary myelofibrosis(PMF) is to improve the quality of life and prolong the survival of patients. For the patients with PMF, stratification based on the efficacy of ruxolitinib and profound genetic detection is a reasonable supplement to the existing of stratification of clinical risk.